A new corporate brand identity features the theme, âEURoeMore Control. Less Risk.âEUR The message reflects St. Jude MedicalâEUR(TM)s dedication to advancing the practice of medicine by focusing on reducing risk wherever possible and contributing to successful outcomes for every patient. The company is developing new technologies to address a growing list of neurological disorders. Clinical studies are currently under way for ParkinsonâEUR(TM)s disease, essential tremor, migraine headaches and major depressive disorder among others. St. Jude Medical is showcasing the worldâEUR(TM)s smallest neurostimulator for chronic pain, the Eon Mini, which was launched in September 2008. It is also showing an expanded portfolio of products including EonC, St. Jude MedicalâEUR(TM)s first extended life nonrechargeable neurostimulator, and Cinch anchor, an accessory designed to secure neurostimulation leads to mitigate lead migration. The company is also presenting 15 poster and oral presentations representing research in areas such as deep brain stimulation for depression, peripheral field nerve stimulation for chronic pain, and spinal cord stimulation for chronic pain of the back, arms, and legs. These presentations reflect on the ongoing collaboration with physicians to develop new therapies for patients who have exhausted most other therapeutic options.